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Monoclonal gammopathyAbstract Background: Plasma cell dyscrasias (PCDs) refer to a spectrum of disorders character-
ized by the monoclonal proliferation of lymphoplasmacytic cells in the bone marrow and, some-
times, tissue deposition of monoclonal immunoglobulins or their components. These disorders
include multiple myeloma (MM) and Waldenstro¨m’s macroglobulinemia, as well as rare conditions
such as light-chain deposition disease (LCDD) and heavy-chain diseases (HCDs). The worldwide
annual incidence of MM is estimated at 86,000, which is approximately 0.8% of all new cancer
cases.
Purpose: Our retrospective study aims to highlight the immunologic and epidemiological features
of PCDs mainly MM in Egyptian patients and compare our results with those of other populations.
Methods: Two hundred seventeen Egyptian patients with PCD were enrolled in the study. Serum,
urine protein electrophoresis and immunoﬁxation were used to demonstrate M protein.
Results: One hundred thirty-eight patients (63.6%) had IgG monoclonal band, 38 patients (17.5%)
had IgA, 12 patients (5.5%) had Waldenstro¨m’s macroglobulinemia (IgM monoclonal band) and 29
patients (13.4%) were light chain myeloma. One hundred ﬁfty-one (70%) were Kappa chain positive
and 66 patients (30%) were lumbda positive. Conventional cytogenetics was available for 40 patients;
of them12 patients (30%) showed 13q-. Mean OS was 37.5 months (1–84 months). Survival analysis
was statistically insigniﬁcant according to age, sex and ISS or type of treatment (P value > 0.05).
68 N.M. Kassem et al.Conclusion: Long term follow up is required to further deﬁne the role of different therapeutic lines of
treatment including ASCT in the various stages of PCD based on OS data.
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Plasma cell dyscrasias (PCDs) constitute a broad spectrum of
diseases characterized by clonal proliferation and accumulation
of cells producing monoclonal immunoglobulins (M compo-
nent) and include monoclonal gammopathy of undetermined
signiﬁcance (MGUS), multiple myeloma (MM), smoldering
multiple myeloma (SMM), plasma cell leukemia (PCL), Wald-
enstro¨m’s macroglobulinemia (WM), POEMS syndrome, plas-
macytoma, heavy chain disease (HCD), and amyloidosis [1].
Multiple myeloma is the most serious and prevalent plasma
cell dyscrasia and accounts for approximately 10% of all
hematologic cancers [2,3]. It usually evolves from an asymp-
tomatic premalignant stage of clonal plasma cell proliferation
termed ‘‘monoclonal gammopathy of undetermined signiﬁ-
cance’’ (MGUS). MGUS is present in more than 3% of the
population above the age of 50 and progresses to myeloma
or related malignancy at a rate of 1% per year [4,5]. In some
patients, an intermediate asymptomatic but more advanced
premalignant stage, referred to as ‘‘smoldering multiple myelo-
ma’’, is clinically recognized [6].
The worldwide annual incidence of MM is estimated at
86,000, which is approximately 0.8% of all new cancer cases
[7]. Approximately 63,000 deaths are reported annually, which
is 0.9% of all cancer-related deaths [7]. The American Cancer
Society estimates that in 2013, there will be 22,350 cases of
MM diagnosed (12,440 in men and 9910 in women) and
10,710 deaths related to MM (6070 in men and 4640 in wo-
men) in the United States. The incidence rate of multiple mye-
loma was signiﬁcantly higher among people living in urban
areas than those from rural areas. Residents of urban areas
may expose to some carcinogenic factors especially those re-
lated to the development of multiple myeloma. Previous stud-
ies suggested that exposure to engine exhaust, asbestos and
benzene may increase the risk of multiple myeloma [8].
Diagnosis of MM is based on the presence of a monoclonal
protein, bone manifestations and on bone marrow (BM) plas-
ma cell inﬁltration. Patients with multiple myeloma must be
distinguished from those with monoclonal gammopathy of
undetermined signiﬁcance [<10% BM plasma cell inﬁltration,
low M-component levels (<3 g/dl) and no osteolytic bone le-
sions] and those with amyloidosis or other lymphoproliferative
disorders with paraproteinemia. Recent guidelines recommend
differentiating between symptomatic and asymptomatic mye-
loma. Symptomatic patients present with one or more of the
CRAB criteria (hypercalcemia, renal failure, anemia, bone le-
sions) and need active treatment, in contrast to asymptomatic
patients, which should be followed only [9].
The disease is relatively rare and the prognosis is poor with
a 5-year relative survival of 38.5%. The older age, male gender,
black race, family history of the disease and MGUS are all risk
factors [10]. The increase in mortality rate has been reported in
Japan, Italy, France, Germany, and Wales. Overall, mortality
rates are highest among patients older than 85 years. In
England and Wales, the mortality rates for men and womenaged 70–74 years were higher during the period 1981–1985
compared with 1970–1980, whereas the corresponding rates
stabilized over time in the younger age groups [11].
The combination of melphalan and prednisone produces re-
sponses in approximately 50% of patients and a disease-free
survival (DFS) of approximately 15 months. Meta-analysis
comparing combination chemotherapy with melphalan and
prednisone has shown no statistically signiﬁcant difference in
survival, despite a higher response rate with more aggressive
combination chemotherapy. The VAD regimen (infusional
vincristine and doxorubicin combined with dexamethasone)
results in a response rate of about 70% and does not compro-
mise stem cell collection unlike melphalan [12].
Thalidomide, an oral immunomodulatory drug, is efﬁca-
cious for patients with relapsed and refractory multiple myelo-
ma. It has been combined with dexamethasone, and a recent
clinical trial noted a higher response rate (70%) with that com-
bination when compared with dexamethasone alone (50%)
[13]. More recently, lenalidomide (a thalidomide analog), and
bortezomib (a proteasome inhibitor) are evaluated in different
combinations with chemotherapy, dexamethasone, or both.
Survival information is as yet inconclusive for these combina-
tions [14].
In this retrospective study, we try to review the epidemio-
logical features and survival of PCDs patients diagnosed and
treated in the period between 2000 and 2010 and compare
our results with other studies.
Patients and methods
Study population
The current study was carried out on 217 Egyptian patients
with PCDs. Patients were chosen during the period between
‘‘2000 and 2010’’ among cases referred to the clinical oncology
department, Cairo University. The research was approved by
the IRB of the clinical oncology department, Cairo University.
They were 128 males and 89 females. Their ages ranged be-
tween 27 and 80 years with a mean age of 58.5 years and med-
ian of 53.5 years.
All patients were subjected to: 1. Routine Laboratory Tests
including, Complete blood count with differential count, com-
plete metabolic panel (calcium, albumin, and creatinine) and
coagulation testing. 2. Myeloma-Speciﬁc Testing including,
serum protein electrophoresis, monoclonal protein analysis
by immunoﬁxation, urine protein electrophoresis, serum
b2-microglobulin, CRP, and LDH, BM aspirate and biopsy,
ﬂow cytometry (CD38 & CD138) and 3. Skeletal bone survey
including, plain X-ray ﬁlms of the spine, pelvis, skull, humeri,
and femurs.
Prognostic criteria for MM were applied according to the
International Staging System (ISS) (Table 1), which provides
two advantages over the traditional Durie–Salmon system.
The ISS relies on widely available laboratory parameters and
allocates patients to equally sized patients groups with
Table 2 Age distribution of 217 patients with plasma cell
dyscrasias.
Age (ys) Patient (%)
<40 4
40–49 9
50–59 39
60–69 38
70–79 9
P80 1
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system depends on the subjective evaluation of the extent of
bone involvement and usually results in an imbalanced distri-
bution of patients (more patients are categorized as stage III
than as stage I or II) [15].
Statistical method
Data showed non-parametric distribution &Mann–Whitney U
test was used for comparisons between two groups. This test is
the non-parametric alternative to Student’s t-test.
Chi-square (v2) test was used for studying the comparisons
and associations between different qualitative variables. Spear-
man’s correlation coefﬁcient was used to determine signiﬁcant
correlations between different variables.
The Kaplan–Meier survival curve was constructed for sur-
vival analysis.
The signiﬁcance level was set at P 6 0.05.
Statistical analysis was performed with IBM/SPSS Statistics
Version 20 for Windows.
Results
The study included 128 (59%) males and 89 (41%) females.
Their ages ranged between 27 and 80 years with a mean age
of 58.5 years and median of 53.5 years (Table 2).
Regarding immunoglobulin subtypes, one hundred thirty-
eight patients (63.6%) had IgG monoclonal band, 38 patients
(17.5%) had IgA, 12 patients (5.5%) had Waldenstro¨m’s mac-
roglobulinemia (IgM monoclonal band) and 29 patients
(13.4%) were light chain myeloma. One hundred ﬁfty-one
(70%) were Kappa chain positive and 66 patients (30%) were
lumbda positive.
Survival analysis calculated for 116 patients: Mean overall
survival was 37.5 ± 16.89 months (1–84 months) and median
survival was 15.8 months. Thirty-one patients (27%) with
ISS = I mean survival was 21.9 ± 13.8 months and median
survival was 15.8 months. Seventy-eight patients (67%) with
ISS stage II mean survival was 20.5 ± 15.9 months and med-
ian survival was 14.5 months. Seven patients (6%) with
ISS = III mean survival was 16.6 ± 9.09 months and median
survival was 12 months. ANOVA test for comparison of
difference according to age, sex and ISS was used. Survival
analysis was statistically insigniﬁcant (P value > 0.05). Fig. 1
demonstrates survival difference according to ISS (P value
0.4). Figs. 2 and 3 compare survival difference between two
age groups (below 50 and above 50 years) and sex, respectively
and was statistically insigniﬁcant (P value > 0.05).
Conventional cytogenetics was available for 40 patients. 12
patients (30%) were 13q- by the FISH technique.Table 1 The International Staging System.
Stage Deﬁnition
I Albumin > 3.5 g/dl and
b2-Microglobulin < 3.5 mg/dl
II Albumin < 3.5 g/dl and
b2-Microglobulin < 3.5 mg/dl or
b2-Microglobulin 3.5–5.5 mg/dl
III b2-Microglobulin > 5.5 mg/dlData regarding treatment were complete for 55 patients
mentioned in Table 3. Around 50% of patients received endo-
xan/steroids or melphalan/steroids. Survival analysis accord-
ing to treatment type was statistically insigniﬁcant (Fig. 4).
Discussion
The aim of this study is to highlight the immunologic and epi-
demiological features of PCDs in Egyptian patients and com-
pare our results with those of other populations. This study
included 205 MM patients presented to Cairo University
between ‘‘2000 and 2010’’. Mean age studied was 58.5 years
(27–80 years). This is not consistent with most western pub-
lished reports that conﬁrmed the rising incidence of MM and
the hypothesis that myeloma is a genetically evolutionary dis-
ease [16]. However, our mean age was similar to a Chinese
study where the median onset age was 58 years with a spike
of 55–65 years [17]. In US age-adjusted incidence rates accord-
ing to age group, MM is rarely diagnosed prior to age 40, after
which the incidence increases rapidly until age 84 and then de-
clines [18,19]. The median age in England (Thames region) was
72 years [20] and Swedish study, did report a median age of
72 years [21].
Males’ percentage was higher than females (59% vs. 41%).
This is similar to what was reported in the South Thames area0.00 20.00 40.00 60.00 80.00 100.00
survival
0.0
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Figure 1 Survival according to ISS score of 116 patients with
plasma cell dyscrasias.
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Figure 2 Kaplan survival according to age group of 217 patients
with plasma cell dyscrasias.
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Figure 3 Kaplan–Meier survival curve according to sex of 217
patients with plasma cell dyscrasias.
Table 3 Treatment of MM patients.
Treatment Number of
patients
Survival in
months (mean ± SD)
Endoxan/melphalan steroid 27 (49%) 50 ± 4.9
VAD 12 (22%) 47.4 ± 9.8
Velcade 3 (5 %) 30.89 ± 8.4
Thalidomide 13 (24%) 25.5 ± 3.8
0.00 50.00 100.00 150.00
survival in months
0.0
0.2
0.4
0.6
0.8
1.0
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VAD
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Figure 4 Kaplan–Meier survival curve according to treatment of
55 patients with MM.
70 N.M. Kassem et al.epidemiology study and Chinese study [18,20]. Our results are
similar to those of Mayo clinic study where 59% of 1072 were
males and Los Anglos [14,22]. SEER (US Surveillance Epide-
miology and End Results Programme) data from 1992 to 1998
revealed a male to female ratio of 1.4–1 [20].
The commonest type of immunoglobulin in our study was
IgG which was found in more than 60% followed by IgAand light chain myeloma. This is consistent with that reported
in Mayo Clinic [14].
Our mean OS was 37.5 ± 16.89 months and median
survival was 15.8 months. No difference between young and
elderly (cut age level was 50 years). While mean survival in
the SEER study, a large study on epidemiology of MM. was
30 months (median = 19 months). Multivariate analysis did
not reveal statistically signiﬁcant differences in OS between pa-
tients in the white and black race (P= 0.709). Younger age
(age less than 65, and 65–75) was associated with improved
OS when compared with patients more than 75 years of age
(P: 0.001) [23]. In our work we used cut level of 50 years as
age level not 65 years as in the SEER due to decrease life expec-
tancy age in our population in comparison to western coun-
tries. The lack of a signiﬁcant difference in survival between
different groups could be attributed to the small patient num-
bers in the group below 50 years in relation to the other group.
MMremains generally incurable, withmost patients experienc-
ing relapse after ﬁrst-line treatment. Median survival is approxi-
mately 5 years [24]. The goals of ﬁrst-line therapy are to achieve
rapid disease control with prolonged remissions and to produce
substantial cytoreduction. Achievement of a complete response
(CR) is an important goal, because it has been shown to be prog-
nostic for improved survival when achieved after HDT–ASCT,
after induction therapy before HDT–ASCT or after induction
therapy in patients not proceeding to HDT–ASCT [25].
Data regarding treatment were complete for 55 patients.
Front line therapy; endoxan and dexamethasone were the
main line of treatment of most of the patients (49% with OS
47 months). Twelve patients (22%) received VAD regimen
(adriamycin, vincristin and decadrone). Due to ﬁnancial as-
pects, 24% received thalidomide and only 5% received velcade
either alone or in combination. That could be the cause of
inability to see a statistical signiﬁcant difference in overall sur-
vival among different groups according to treatment subtypes.
Newer agents were preserved to those who showed unfavor-
able cytogenetics as 13q-.
A descriptive study of plasma cell dyscrasias in Egyptian population 71Mean survival is a little bit lower to that reported in
another Egyptian study done on 35 newly diagnosed MM
patients with OS being 42 months [26], in Iranian study, sur-
vival was 44.3 months [27] and in Chinese large study was
40 months but nearer to those of western countries [17] which
could be attributed to ethnic variations.
Conclusion
Long term follow up is required to further deﬁne the role of
different therapeutic lines of treatment including ASCT in
the various stages of PCD based on OS data. Tailoring of
therapies to individual cytogenetic risk factors should also be
considered. A number of anti myeloma agents are currently
undergoing examination in clinical trials such as HSP90 inhib-
itors, HDAC inhibitors. Results from ongoing studies will
certainly affect the future of the disease outcome.
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